Pharmaceutical

EC approves Celltrion’s Omlyclo for allergic conditions

The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference product Xolair to treat allergic conditions.

May 25, 2024 - 04:00
EC approves Celltrion’s Omlyclo for allergic conditions
The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference product Xolair to treat allergic conditions.
Read the original article

Tags:

Previous Article

Cystic fibrosis: global clinical trials landscape and treatments

Next Article

Biocon and Handok link to commercialise Liraglutide in South Korea

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca mulls risk strategy for Ultomiris following FDA response letter

AstraZeneca mulls risk strategy for Ultomiris following...

Sep 7, 2023

‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs

‘Robbing Peter to pay Paul’: Obesity experts debate ris...

May 9, 2023

Opinion: There’s a less intimidating alternative to EpiPens for dangerous allergic reactions. Why won’t the FDA approve it?

Opinion: There’s a less intimidating alternative to Epi...

Dec 29, 2023